Renal therapeutics Market Research Reports

The global kidney and renal diseases market represented steady growth for its four indications, chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury. The forecast represents high growth in diagnosis rates, strong pipeline products and safety, efficacy and more survival rates while the treatment is ongoing.

The renal disease therapeutics market supports with the increase in the number of kidney transplantation, improvement in drug treatments and building stronger patient confidence in the procedure. Also, the options are available to treat the diseases by using novel drugs with other new technology, such as stem cell therapy and immunoglobulin therapy. The kidney organ transplantation market reduced globally due to the generic erosion of immuno suppressant drugs used for kidney transplantation maintenance.

Most of the renal disease global market revenues inncreased due to the approval of pipeline products, introduction of new therapies suc...
View More

The global kidney and renal diseases market represented steady growth for its four indications, chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury. The forecast represents high growth in diagnosis rates, strong pipeline products and safety, efficacy and more survival rates while the treatment is ongoing.

The renal disease therapeutics market supports with the increase in the number of kidney transplantation, improvement in drug treatments and building stronger patient confidence in the procedure. Also, the options are available to treat the diseases by using novel drugs with other new technology, such as stem cell therapy and immunoglobulin therapy. The kidney organ transplantation market reduced globally due to the generic erosion of immuno suppressant drugs used for kidney transplantation maintenance.

Most of the renal disease global market revenues inncreased due to the approval of pipeline products, introduction of new therapies such as antioxidant inflammatory modulators, metal-free phosphate binders and the products in the filing or later stage development phase. In the near future, the companies are developing eight molecules which are in various clinical development stages.

The introduction of these new molecules helps the kidney and renal diseases therapeutics market to address the current unmet needs. US is the biggest kidney and renal diseases therapeutics market followed by Europe (UK, Germany, France, Italy, Spain) and Japan. Major global players for renal disease market include Pfizer Inc., Novartis AG, Wilex AG, Antigenics Inc., and Sanofi-Aventis.